Short-time interruption of second-line mycophenolate treatment in a patient with renal sarcoidosis enabled a marked antibody response to SARS-CoV-2 messenger RNA vaccine. | Clin Kidney J;15(3): 584-586, 2022 Mar. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Short-time interruption of second-line mycophenolate treatment in a patient with renal sarcoidosis enabled a marked antibody response to SARS-CoV-2 messenger RNA vaccine.

Schnuelle, Peter; Kölling, Sebastian; Müller, Alexander; Schmitt, Wilhelm H.

Affiliation

Schnuelle P; Center for Renal Diseases Weinheim, Weinheim, Germany.
Kölling S; Center for Renal Diseases Weinheim, Weinheim, Germany.
Müller A; Center for Renal Diseases Weinheim, Weinheim, Germany.
Schmitt WH; Center for Renal Diseases Weinheim, Weinheim, Germany.

Clin Kidney J ; 15(3): 584-586, 2022 Mar.

Article in En | MEDLINE | ID: mdl-35211315

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Kidney J Year: 2022 Document type: Article Affiliation country: Alemania Country of publication: Reino Unido

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Kidney J Year: 2022 Document type: Article Affiliation country: Alemania Country of publication: Reino Unido